Patents Assigned to Genor Biopharma Co. Ltd
-
Patent number: 10253108Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO: 12, SEQ ID NO: 2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.Type: GrantFiled: December 8, 2015Date of Patent: April 9, 2019Assignee: Genor Biopharma Co., Ltd.Inventors: Qing Zhou, Mengjun Shu, Zhuzi He, Jun Lin
-
Patent number: 10017555Abstract: The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.Type: GrantFiled: July 2, 2014Date of Patent: July 10, 2018Assignee: Genor Biopharma Co., LtdInventors: Joe Zhou, Qing Zhou, Rulei Chen, Shu Shi, Weihong Nian, Hongbin Yan
-
Patent number: 9896510Abstract: An anti-human RANKL antibody, a humanized antibody for the anti-human RANKL antibody, a pharmaceutical composition and a use thereof are provided. The anti-human RANKL antibody is capable of bonding specifically with an amino acid sequence of SEQ ID NO.1, a heavy chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.2-9, and a light chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.10-17. The humanized antibody is capable of bonding specifically with human RANKL, a variable region in a heavy chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.6, NO.23, NO.25, NO.27 or NO.29, and a variable region in a light chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.14, NO.31, NO.33, NO.35, NO.37 or NO.39.Type: GrantFiled: December 23, 2015Date of Patent: February 20, 2018Assignee: Genor Biopharma Co., Ltd.Inventors: Qing Zhou, Xiao Feng, Weihong Nian, Lingyun Li
-
Publication number: 20170037146Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO:12, SEQ ID NO:2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.Type: ApplicationFiled: December 8, 2015Publication date: February 9, 2017Applicant: Genor Biopharma Co., LtdInventors: Qing Zhou, Mengjun Shu, Zhuzi He, Jun Lin
-
Publication number: 20160333101Abstract: An anti-human RANKL antibody, a humanized antibody for the anti-human RANKL antibody, a pharmaceutical composition and a use thereof are provided. The anti-human RANKL antibody is capable of bonding specifically with an amino acid sequence of SEQ ID NO.1, a heavy chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.2-9, and a light chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.10-17. The humanized antibody is capable of bonding specifically with human RANKL, a variable region in a heavy chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.6, NO.23, NO.25, NO.27 or NO.29, and a variable region in a light chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.14, NO.31, NO.33, NO.35, NO.37 or NO.39.Type: ApplicationFiled: December 23, 2015Publication date: November 17, 2016Applicant: Genor Biopharma Co., Ltd.Inventors: Qing Zhou, Xiao Feng, Weihong Nian, Lingyun Li
-
Publication number: 20160222079Abstract: The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.Type: ApplicationFiled: July 2, 2014Publication date: August 4, 2016Applicant: Genor Biopharma Co., Ltd.Inventors: Joe ZHOU, Qing ZHOU, Rulei CHEN, Shu SHI, Weihong NIAN, Hongbin YAN
-
Patent number: 8926972Abstract: The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth.Type: GrantFiled: March 18, 2010Date of Patent: January 6, 2015Assignee: Genor Biopharma Co. LtdInventors: Joe Zhou, Jianyang Zhao, Jiuru Sun, Jun Wang, Shaoxiong Wang, Xinxing Ma, Jun Lin